[Use of aldactone-saltucine for patients with chronic circulatory insufficiency].
In 50 patients with congestive heart failure a compound diuretic drug aldactone--saltucine was used. Diuresis, urine excretion of sodium and potassium, rate of glomerular filtration and tubular reabsorption of water, as shown by endogenous creatinin, were measured in all patients. In 13 patients the study was conducted dynamically in 8 three-hour portions of urine during 24 hours. In 6 patients the drug was administred in combination with furosemid. In 11 patients the effect of several days of therapy with aldactone-saltucine upon the urine excretion of electrolytes and their plasma level was studied. The effect of the compound drug was evaluated separately in patients with IIA, IIB and III stage of circulatory insufficiency. Aldactone-saltucine was shown to execute a distinct diuretic and natriuretic effect that lasts for 24 hours after a single dose. The drug has also a clear potassium-preserving action that manifests itself in a low level of potassium excretion with urine and an elevation of a potassium plasma level. A combination of aldactone-saltucine with furosemid considerably increases diuresis and natriuresis, without any signifcant increase in potassiuresis, which permits to use these drugs in the severest cases of congestive heart failure.
D000328:Adult; D000368:Aged; D002073:Butanes / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006852:Hydrochlorothiazide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007684:Kidney Tubules / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011188:Potassium / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use*; D013997:Time Factors
D002073:Butanes; D004232:Diuretics; D004338:Drug Combinations; D006852:Hydrochlorothiazide; D013148:Spironolactone; D005665:Furosemide; D003404:Creatinine; D011188:Potassium
Primenenie al'dakton-sal'tutsina u bol'nykh s khronicheskoĭ nedostatochnost'iu krovoobrashcheniia